Construction of an immune‐related LncRNA signature with prognostic significance for bladder cancer

Luo, Wenjie; Tian, Xi; Xu, Wenhao; Qu, Yuanyuan; Zhu, Wenkai; Wu, Jie; Ma, Chao; Zhang, Hai-Liang; Ye, Dingwei; Zhu, Yiping

doi:10.1111/jcmm.16494

Cited by 22 publications

(23 citation statements)

References 46 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of the public dataset (TCGA-BLCA cohort and GSE89006 in GEO database) suggested that RP11-89 was upregulated in BLCA and closely associated with prognosis of BLCA patients in the previous study [ 25 ]. As shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…The immune microenvironment is critical in BLCA treatments, especially in immunotherapies such as BCG instillation and immune checkpoint inhibitor [42,43]. We previously identified a novel immune related lncRNA signature with prognostic significance for BLCA and RP11-89, one of lncRNAs in the signature, was demonstrated to play an oncogenic role through inhibiting regulated cell death [25]. Chen et al demonstrated that the underlying mechanism for ferroptosis in immune regulation could be explained by immune surveillance, which indicated that tumor cell ferroptosis and tumor suppress could be triggered or enhanced by immune interventions [13].…”

Section: Discussionmentioning

confidence: 99%

“…We previously identified a novel prognostic lncRNA signature related to the immune environment for BLCA by systematic bioinformatic discovery, and RP11-89, one of lncRNAs in the signature, was found to play an oncogenic role in BLCA through inhibiting regulated cell death [ 25 ]. In the current study, we focused on the regulation of ferroptosis resistance by RP11-89 and further investigated the role of RP11-89 in the tumorigenesis of BLCA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer

Luo

Wang

et al. 2021

Cell Death Dis

Self Cite

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) act as important regulators of tumorigenesis and development in bladder cancer. However, the underlying molecular mechanisms remain elusive. We previously identified a novel lncRNA signature related to immunity and progression in bladder cancer. Here we further explored the function of RP11-89, a lncRNA discovered in the previous signature. Loss- and gain-of function experiments were performed using CCK-8 assay, flow cytometry, Transwell assays, scratch tests and subcutaneous nude mouse models. High-throughput RNA sequencing was conducted to identify dysregulated genes in bladder cancer cells with RP11-89 knockdown or overexpression. Regulation of RP11-89 on miR-129-5p and PROM2 was explored through luciferase reporter assay, RIP assay and RNA pull-down assay. RP11-89 promoted cell proliferation, migration and tumorigenesis and inhibited cell cycle arrest via the miR-129-5p/PROM2 axis. We found that RP11-89 “sponges” miR-129-5p and upregulates PROM2. Elevated PROM2 in cells was associated with attenuated ferroptosis through iron export, formation of multivesicular bodies and less mitochondrial abnormalities. We demonstrated that RP11-89 is a novel tumorigenic regulator that inhibits ferroptosis via PROM2-activated iron export. RP11-89 may serve as a potential biomarker for targeted therapy in bladder cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer

Luo

Wang

et al. 2021

Cell Death Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…LncRNAs have been con rmed to be in relation to cancer immunity regulation as well as tumor microenvironment in bladder cancer 17 . Several immune-related lncRNA models have been constructed in published literature 14,18,19 . Nevertheless, these signature models are developed on the basis of expression quanti cations of immune-related lncRNAs.…”

Section: Discussionmentioning

confidence: 99%

An Immune-Related lncRNA Model for Predicting Prognosis, Immune Landscape and Chemotherapeutic Response in Bladder Cancer

Hou¹,

Liang²,

Xie³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: Long noncoding RNAs (lncRNAs) participate in cancer immunity. Herein, we characterized the clinical significance of immune-related lncRNA model and its associations with immune infiltrations and chemosensitivity in bladder cancer.Methods: Transcriptome data of bladder cancer specimens were employed from The Cancer Genome Atlas. Dysregulated immune-related lncRNAs were screened via Pearson correlation and differential expression analyses, followed by recognition of lncRNA pairs. Then, a LASSO regression model was constructed. Receiver operator characteristic curves of one-, three- and five-year survival were plotted. Akaike information criterion (AIC) value of one-year survival was determined as the cutoff of high- and low-risk subgroups. The differences in survival, clinical features, immune cell infiltrations and chemosensitivity were compared between subgroups.Results: Totally, 90 immune-related lncRNA pairs were selected, 15 of which were put into the prognostic model. The area under the curves of one-, three- and five-year survival were 0.806, 0.825 and 0.828, confirming the favorable predictive performance of this model. According to the AIC value, we clustered subjects into high- and low-risk subgroups. High-risk score indicated unfavorable outcomes. This risk model was in relation to survival status, age, stage and TNM. In comparison to conventional clinicopathological characteristics, the risk model displayed higher predictive efficacy and was an independent predictor. Also, it could well characterize immune cell infiltration landscape and predict immune checkpoint expression and sensitivity to cisplatin and methotrexate.Conclusion: This model conducted by paring immune-related lncRNAs regardless of expressions exhibited a favorable efficacy in predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer.

show abstract

“…Linc00936/miR-425-5p/ZC3H12A axis functioned to promote cytokine induced killer cell cytotoxicity and suppress immune escape by decreasing the contents of immunosuppressive factors VEGF, IL-10, and TGF-β1 in GC ( Li et al, 2021 ). Moreover, immune-related lncRNA (IRlncRNA) can be used to establish a model to predict prognosis in cancers ( Chen et al, 2020 ; Luo et al, 2021 ; Wang et al, 2021 ; Zhao K. et al, 2021 ). However, due to difference in data processing, the absolute expression level of genes and lncRNAs between different datasets cannot be compared directly, and appropriate normalizations and standardizations of the lncRNA expression levels are required.…”

Section: Introductionmentioning

confidence: 99%

Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer

Song

Liu

Wei

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: Gastric cancer (GC) remains one of the most malignant tumors around the world, and an accurate model that reliably predicts survival and therapeutic efficacy is urgently needed. As a novel predictor for prognosis in a variety of cancers, immune-related long noncoding RNA pairs (IRlncRNAPs) have been reported to predict tumor prognosis. Herein, we integrated an IRlncRNAPs model to predict the clinical outcome, immune features, and chemotherapeutic efficacy of GC.Methods: Based on the GC data obtained from The Cancer Genome Atlas (TCGA) database and the Immunology Database and Analysis Portal (ImmPort), differentially expressed immune-related long noncoding RNAs (DEIRlncRNAs) were identified. Least absolute shrinkage and selection operator (LASSO) regression and Cox regression analysis were used to select the most appropriate overall survival (OS)-related IRlncRNAPs to develop a prognostic signature. The riskScore of each sample was calculated by comparing the long noncoding RNA expression level in each IRlncRNAP. Based on the riskScore for each patient, GC patients were divided into high- and low-risk groups. Then, the correlation of the signature and riskScore with OS, clinical features, immune cell infiltration, immune-related gene (IRG) expression and chemotherapeutic efficacy in GC was analyzed.Results: A total of 107 DEIRlncRNAs were identified which formed 4297 IRlncRNAPs. Fifteen OS-related IRlncRNAPs were selected to develop a prognostic model. GC patients could be accurately classified into high- and low-risk groups according to the riskScore of the prognostic model. The 1-, 2-, 3-, and 5-year receiver operating characteristic (ROC) curves for the riskScore were drawn and the area under the curve (AUC) values were found to be 0.788, 0.810, 0.825, and 0.868, respectively, demonstrating a high sensitivity and accuracy of this prognostic signature. Moreover, the immune-related riskScore was an independent risk factor. Patients showed a poorer outcome within the high-risk group. In addition, the riskScore was found to be significantly correlated with the clinical features, immune infiltration status, IRG expression, and chemotherapeutic efficacy in GC.Conclusion: The prognostic model of IRlncRNAPs offers great promise in predicting the prognosis, immune infiltration status, and chemotherapeutic efficacy in GC, which might be helpful for the selection of chemo- and immuno-therapy of GC.

show abstract

Construction of an immune‐related LncRNA signature with prognostic significance for bladder cancer

Cited by 22 publications

References 46 publications

LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer

LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer

An Immune-Related lncRNA Model for Predicting Prognosis, Immune Landscape and Chemotherapeutic Response in Bladder Cancer

Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer

Contact Info

Product

Resources

About